- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.04. | Novo Nordisk outlays $1.09bn to boost GLP-1RA production in Brazil | ||
| 09.04. | US to impose tariffs on pharmaceutical imports | ||
| 09.04. | Obesity-related liver conditions: Understanding treatment options | ||
| 09.04. | AbbVie's upadacitinib gains EU marketing authorisation for GCA | ||
| 08.04. | Epsilogen acquires TigaTx to expand pan-isotope cancer antibody pipeline | ||
| 08.04. | KalVista licenses commercialisation rights for HAE to Kaken in Japan | ||
| 08.04. | UK Government to invest $764m into new health data service | ||
| 08.04. | EU president to meet pharma leaders as tariff threat looms | ||
| 08.04. | Ethris and Lonza to develop mRNA vaccines for respiratory conditions | ||
| 08.04. | Africa: The clinical impact of the US withdrawal from WHO and USAID | ||
| 08.04. | EC approves extension of indication for Janssen-Cilag's Darzalex | ||
| 08.04. | AD/PD 2025: Reporting of first real-world data for Leqembi focuses on operational challenges and safety | ||
| 07.04. | AD/PD 2025: First real-world data report for Leqembi focuses on operational challenges | ||
| 07.04. | China's NMPA authorises Santen's glaucoma treatment application | ||
| 07.04. | Obesity drugs won't be covered by Medicare under 2026 CMS policy | ||
| 07.04. | EC approves AstraZeneca's Imfinzi combo for NSCLC | ||
| 07.04. | ABL Bio and GSK link on neurodegenerative conditions | ||
| 04.04. | Uveitis market expected to reach $1.5bn across 7MM by 2033 | ||
| 04.04. | Daiichi and AstraZeneca's Enhertu gains EC approval for breast cancers | ||
| 04.04. | 'Fear and uncertainty' linger over FDA's future in wake of Trump admin's layoffs | ||
| 04.04. | Streeting promises UK pharma quick action on VPAG frustration | ||
| 04.04. | NBE Therapeutics opens ADC research facility in Switzerland | ||
| 04.04. | Digital cognitive assessments and blood-based biomarkers in Alzheimer's research | ||
| 04.04. | FDA awards ODD status to Sanofi's rilzabrutinib for two rare conditions | ||
| 03.04. | Neurona raises $102m to advance cell therapy for drug-resistant epilepsy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
